Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 plus leucovorin versus S-1 in gemcitabine-refractory pancreatic cancer
jRCT2080221515Phase 2
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jul 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic adenocarcinoma (PDAC) comparing S-1 plus leucovorin with S-1 monotherapy (2 arms).
02
Drugs
tegafurfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2080221515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221515.